ESR1 and breast carcinoma: The Low-ER subgroup comprised 12.6% of our study population; this finding is consistent with previous studies which have shown that this group accounts for 8–16% of HER2-negative ER/PR-negative breast cancers, with different definitions of ER/PR negativity being utilized across studies18,23,24.